Examinando por Autor "Torres-Macho, Juan"

Mostrando 1 - 6 de 6

Clustering analysis reveals different profiles associating long-term post-COVID symptoms, COVID-19 symptoms at hospital admission and previous medical co-morbidities in previously hospitalized COVID-19 survivors
(Springer, 2022) Fernández-de-las-Peñas, César; Martín-Guerrero, José D.; Florencio, Lidiane L.; Navarro-Pardo, Esperanza; Rodríguez-Jiménez, Jorge; Torres-Macho, Juan; Pellicer-Valero, Oscar J.
Purpose To identify subgroups of COVID-19 survivors exhibiting long-term post-COVID symptoms according to clinical/ hospitalization data by using cluster analysis in order to foresee the illness progress and facilitate subsequent prognosis. Methods Age, gender, height, weight, pre-existing medical comorbidities, Internal Care Unit (ICU) admission, days at hospital, and presence of COVID-19 symptoms at hospital admission were collected from hospital records in a sample of patients recovered from COVID-19 at fve hospitals in Madrid (Spain). A predefned list of post-COVID symptoms was systematically assessed a mean of 8.4 months (SD 15.5) after hospital discharge. Anxiety/depressive levels and sleep quality were assessed with the Hospital Anxiety and Depression Scale and Pittsburgh Sleep Quality Index, respectively. Cluster analysis was used to identify groupings of COVID-19 patients without introducing any previous assumptions, yielding three diferent clusters associating post-COVID symptoms with acute COVID-19 symptoms at hospital admission. Results Cluster 2 grouped subjects with lower prevalence of medical co-morbidities, lower number of COVID-19 symptoms at hospital admission, lower number of post-COVID symptoms, and almost no limitations with daily living activities when compared to the others. In contrast, individuals in cluster 0 and 1 exhibited higher number of pre-existing medical co-morbidities, higher number of COVID-19 symptoms at hospital admission, higher number of long-term post-COVID symptoms (particularly fatigue, dyspnea and pain), more limitations on daily living activities, higher anxiety and depressive levels, and worse sleep quality than those in cluster 2. Conclusions The identifed subgrouping may refect diferent mechanisms which should be considered in therapeutic interventions.
DNA Salivary Methylation Levels of the ACE2 Promoter Are Not Related to ACE2 (rs2285666 and rs2074192), TMPRSS2 (rs12329760 and rs2070788) and ACE1 rs1799752 Polymorphisms in COVID-19 Survivors with Post-COVID-19 Condition
(MDPI, 2025-02-27) Fernández-de-las-Peñas, César; Díaz-Gil, Gema; Gil-Crujera, Antonio; Gómez-Sánchez, Stella Maris; Ambite-Quesada, Silvia; Torres-Macho, Juan; Ryan-Murua, Pablo; Franco-Moreno, Ana; Pellicer-Valero, Óscar J.; Arendt-Nielsen, Lars
El artículo publicado en la revista International Journal of Molecular Sciences (IJMS), aborda una cuestión de gran actualidad científica: la interacción entre factores genéticos y epigenéticos en la persistencia de síntomas post-COVID-19. La revista IJMS, editada por MDPI, está indexada en Journal Citation Reports (JCR) y Scopus, y cuenta con un factor de impacto de 5.6 en su edición más reciente (2024), situándose en el primer cuartil (Q1) en las categorías de Bioquímica y Biología Molecular. Además, presenta un CiteScore de 6.4 en Scopus, lo que refleja su consolidada reputación en el ámbito de las ciencias biomédicas y su alta visibilidad internacional. Este estudio, con una muestra de 279 pacientes previamente hospitalizados por COVID-19, analiza si existe una relación entre los niveles de metilación del promotor del gen ACE2 y cinco polimorfismos genéticos asociados a la infección por SARS-CoV-2. A través de técnicas avanzadas de pirosecuenciación y genotipado, los autores concluyen que no se observa una asociación significativa entre los perfiles epigenéticos y los genotipos analizados, lo que contribuye a delimitar el papel de estos mecanismos en el desarrollo del síndrome post-COVID. La publicación en una revista de alto impacto, con revisión por pares y posicionamiento Q1, avala la calidad metodológica, el rigor científico y la relevancia clínica del trabajo, cumpliendo con los estándares de excelencia requeridos por ANECA para la evaluación de méritos investigadores.
Effect of platelet rich plasma on sinus lifting: A randomized controlled clinical trial
(2011-12-02) Torres, Jesús; Tamimi, Faleh; Martínez, Pedro Pablo; Alkhraisat, Mohammad; Linares, Rafael; Hernandez, Gonzalo; Torres-Macho, Juan; López-Cabarcos, Enrique
6 7 Objective: The combination of anorganic bovine bone (ABB) with platelet rich plasma ABSTRACT 8 (PRP) has been widely used in bone regeneration procedures although its benefits are 9 10 11 12 13 14 15 16 17 18 19 20 a histology level and any adjunctive effects, we performed an ancillary study in 5 still unclear. The purpose of this study was to evaluate whether or not PRP improves the efficacy of ABB in sinus floor augmentation. In addition, we have investigated the effect of residual bone height and tobacco on implant survival in sinus augmentation procedures. Materials and Methods: 87 patients recruited for this study underwent 144 sinus floor augmentation procedures using ABB alone or ABB plus PRP (ABB+PRP) in a randomized clinical trial. A total of 286 implants were placed in the augmented bone, and their evolution was followed up for a period of 24 months. In order to investigate on 21 edentulous patients with symmetrical severely resorbed maxilla. In these patients, a 22 23 24 25 26 27 Results: Overall, 96.2% of ABB and 98.6% of ABB+PRP implant success was 28 bilateral sinus augmentation was randomly performed using ABB or ABB+PRP in a split-mouth design, and after 6 months, bone biopsies were taken from the implant sites for histological and histomorphometric analysis. obtained during the monitoring period and differences were not found between sites grafted with and without PRP in the 87 patients studied. Densitometry assessments and graft resorption were similar in both experimental groups. However, the histological and histomorphometrical analysis in the 5 edentulous patients revealed that bone 29 30 31 32 33 augmentation was significantly higher in sites treated with ABB+PRP (p¿0.05). 34 Another outcome from our study is that the lack of initial bone support (p¿0.05) and smoking (p=0.05) appeared to have a negative effect on the treatment success, that was accentuated when both circumstances coincided. 35 36 37 38 39 40 procedures. However, this study revealed that PRP can improve the osteoconductive 41 Conclusions: PRP is not a determining factor for implant survival in sinus lifting properties of ABB by increasing the volume of new bone formed. Moreover, in sinus augmentation procedures implant¿s survival rate seems more influenced by the residual bone height or by tobacco than by the type of bone graft. 42 43 44
Headache as a COVID-19 onset symptom and post-COVID-19 symptom in hospitalized COVID-19 survivors infected with the Wuhan, Alpha, or Delta SARS-CoV-2 variants
(Wiley, 2022) Fernández-de-las-Peñas, César; Cuadrado, Maria L.; Gómez-Mayordomo, Victor; Torres-Macho, Juan; Pellicer-Valero, Oscar J.; Martín-Guerrero, José D.; Arendt-Nielsen, Lars
ObjectiveThis study looked at differences in the presence of headache as an onset symptom of coronavirus disease 2019 (COVID-19) and as a post-COVID-19 symptom in individuals previously hospitalized owing to infection with the Wuhan, Alpha, or Delta variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).BackgroundHeadache can be present in up to 50% of individuals during the acute phase of SARS-CoV-2 infection and in 10% of subjects during the post-COVID-19 phase. There are no data on differences in the occurrence of headache in the acute- and post-COVID-19 phase according to the SARS-CoV-2 variants.MethodsA cross-sectional cohort study was conducted. Unvaccinated subjects previously hospitalized for COVID-19 caused by the Wuhan (n = 201), Alpha (n = 211), or Delta (n = 202) SARS-CoV-2 variants were scheduled for a telephone interview 6 months after hospital discharge. Hospitalization data were collected from hospital medical records.ResultsThe presence of headache as a COVID-19 onset symptom at hospitalization was higher in subjects with the Delta variant (66/202, 32.7%) than in those infected with the Wuhan (42/201, 20.9%; odds ratio [OR] 1.83, 95% confidence interval [CI] 1.17–2.88) or Alpha (25/211, 11.8%; OR 3.61, 95% CI, 2.16–6.01) variants. The prevalence of post-COVID-19 headache 6 months after hospital discharge was higher in individuals infected with the Delta variant (26/202, 12.9%) than in those infected with the Wuhan (11/201, 5.5%; OR 2.52, 95% CI 1.22–5.31) or Alpha (eight of 211, 3.8%; OR 3.74, 95% CI 1.65–8.49) variants. The presence of headache as a COVID-19 onset symptom was associated with post-COVID-19 headache in subjects infected with the Wuhan (OR 7.75, 95% CI 2.15–27.93) and Delta variants (OR 2.78, 95% CI 1.20–6.42) but not with the Alpha variant (OR 2.60, 95% CI 0.49–13.69).ConclusionHeadache was a common symptom in both the acute- and post-COVID-19 phase in subjects infected with the Wuhan, Alpha, and Delta variants but mostly in those infected with the Delta variant.
Post-COVID-19 Pain Is Not Associated with DNA Methylation Levels of the ACE2 Promoter in COVID-19 Survivors Hospitalized Due to SARS-CoV-2 Infection
(MDPI, 2024-07-25) Fernández-de-las-Peñas, César; Díaz-Gil, Gema; Gil-Crujera, Antonio; Gómez-Sánchez, Stella Maris; Ambite-Quesda, Silvia; Franco-Moreno, Anabel; Ryan-Murua, Pablo; Torres-Macho, Juan; Pellicer-Valero, Óscar J.; Arendt-Nielsen, Lars; Giordano, Rocco
One of theories explaining the development of long-lasting symptoms after an acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection include changes in the methylation pattern of the host. The current study aimed to investigate whether DNA methylation levels associated with the angiotensin-converting enzyme 2 (ACE2) promoter are different when comparing individuals previously hospitalized due to COVID-19 who then developed long-lasting post-COVID pain with those previously hospitalized due to COVID-19 who did not develop post-COVID-19 pain symptoms. Non-stimulated saliva samples were obtained from a cohort of 279 (mean age: 56.5, SD: 13.0 years old, 51.5% male) COVID-19 survivors who needed hospitalization. Clinical data were collected from hospital medical records. Participants were asked to disclose pain symptoms developed during the first three months after hospital admission due to COVID-19 and persisting at the time of the interview. Methylations of five CpG dinucleotides in the ACE2 promoter were quantified (as percentages). Participants were evaluated up to 17.8 (SD: 5.3) months after hospitalization. Thus, 39.1% of patients exhibited post-COVID-19 pain. Most patients (77.05%) in the cohort developed localized post-COVID-19 pain. Headache and pain in the lower extremity were experienced by 29.4% of the patients. Seven patients received a post-infection diagnosis of fibromyalgia based on the presence of widespread pain characteristics (11.6%) and other associated symptoms. No significant differences in methylation percentages at any CpG location of the ACE2 promoter were identified when comparing individuals with and without post-COVID-19 pain. The current study did not observe differences in methylation levels of the ACE2 promoter depending on the presence or absence of long-lasting post-COVID-19 pain symptoms in individuals who needed hospitalization due to COVID-19 during the first wave of the pandemic.
Presence of SARS-CoV-2 RNA in COVID-19 survivors with post-COVID symptoms 2 years after hospitalization: The VIPER study
(Wiley, 2024-05-15) Fernández-de-las-Peñas, César; Torres-Macho, Juan; Ruiz-Ruigómez, Maria; Arrieta-Ortubay, Estibaliz; Rodríguez-Rebollo, Carolina; Akasbi-Moltalvo, Miriam; Pardo-Guimerá, Virginia; Ryan-Murua, Pablo; Lumbreras-Bermejo, Carlos; Pellicer-Valero, Oscar J.; Giordano, Rocco; Arendt-Nielsen, Lars; Franco-Moreno, Anabel
The SARS-CoV-2 VIrus PERsistence (VIPER) study investigated the presence of long-lasting SARS-CoV-2 RNA in plasma, stool, urine, and nasopharyngeal samples in COVID-19 survivors. The presence of SARS-CoV-2 RNA reverse transcription polymerase chain reactions (RT-PCR) were analyzed within plasma, stool, urine, and nasopharyngeal swab samples in COVID-19 survivors with post-COVID symptoms and a comparison group of COVID-19 survivors without post-COVID symptoms matched by age, sex, body mass index and vaccination status. Participants self-reported the presence of any post-COVID symptom (defined as a symptom that started no later than 3 months after the initial infection). Fifty-seven (57.9% women, age: 51.1, standard deviation [SD]: 10.4 years) previously hospitalized COVID-19 survivors with post-COVID symptoms and 55 (56.4% women, age: 50.0, SD: 12.8 years) matched individuals who had a past SARS-CoV-2 infection without post-COVID symptoms were evaluated 27 (SD 7.5) and 26 (SD 8.7) months after hospital discharge, respectively. The presence of SARS-CoV-2 RNA was identified in three nasopharyngeal samples of patients with post-COVID symptoms (5.2%) but not in plasma, stool, or urine samples. Thus, SARS-CoV-2 RNA was not identified in any sample of survivors without post-COVID symptoms. The most prevalent post-COVID symptoms consisted of fatigue (93%), dyspnea, and pain (both, 87.7%). This study did not find SARS-CoV-2 RNA in plasma, stool, or urine samples, 2 years after the infection. A prevalence of 5.2% of SARS-CoV-2 RNA in nasopharyngeal samples, suggesting a potential active or recent reinfection, was found in patients with post-COVID symptoms. These results do not support the association between SARS-CoV-2 RNA in plasma, stool, urine, or nasopharyngeal swab samples and post-COVID symptomatology in the recruited population